Enanta prices IPO shares at low end of range

Enanta Pharmaceuticals, which is partnered with AbbVie ($ABBV) on a hot new experimental therapy for hepatitis C, has priced its IPO shares at $14. The Watertown, MA developer--a Fierce 15 company--raised $56 million. The biotech priced its shares at the low end of the range, but Enanta is avoiding the deep discounting that was required for other biotechs to complete their maiden offering. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.